Continue reading below
Monday was a devastating day for Coronado Biosciences Inc. — its stock fell 67 percent — and Tuesday just rubbed it in with a 10 percent decline. The Burlington company’s phase 2 clinical trial for its treatment of Crohn’s disease, an immune disorder that causes bowel inflammation, ended badly. Coronado hoped to show that whipworm parasites could be used to trick a Crohn’s patient’s immune system into attacking the worms instead of the intestines. The trial did not meet a primary goal of significantly improving a measure of Crohn’s severity or a secondary goal of achieving remission.